For the year ending 2025-12-31, LGNXZ made $268,087K in revenue. $124,453K in net income. Net profit margin of 46.42%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue and income | 268,087 | |||
| Cost of captisol | 14,549 | |||
| Amortization of intangibles | 32,708 | |||
| Research and development | 81,182 | |||
| General and administrative | 92,449 | |||
| Financial royalty assets impairment | 6,197 | |||
| Fair value adjustments to partner program derivatives | 0 | |||
| Total operating costs and expenses | 227,085 | |||
| Gain on sale of pelican | 0 | |||
| Operating income (loss) from continuing operations | 41,002 | |||
| Gain from short-term investments | 18,433 | |||
| Gain (loss) from change in fair value of equity method investments and other investments | 90,670 | |||
| Interest income | 13,659 | |||
| Interest expense | 4,715 | |||
| Other non-operating expense, net | -89 | |||
| Total non-operating income, net | 117,958 | |||
| Income before income tax from continuing operations | 158,960 | |||
| Income tax expense | 34,507 | |||
| Net income (loss) from continuing operations | 124,453 | |||
| Net income (loss) | 124,453 | |||
| Basic EPS | 6.44 | |||
| Diluted EPS | 6.13 | |||
| Basic Average Shares | 19,338,000 | |||
| Diluted Average Shares | 20,294,000 | |||
LIGAND PHARMACEUTICALS INC (LGNXZ)
LIGAND PHARMACEUTICALS INC (LGNXZ)